Treatment and control groups

Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

Retrieved on: 
Friday, March 8, 2024
Research, General Health, Technology, Medical Devices, Other Manufacturing, Health Technology, Clinical Trials, Science, Biotechnology, Wearables, Mobile Technology, Health, Diabetes, Manufacturing, TIR, Dexcom, CGM, Doctor of Philosophy, Randomized controlled trial, MD, Treatment, Medical director, G6, AID, Intervention, Conference, ATTD, Safety, Hypoglycemia, Control, RCT, T1D, Corporation, DKA, Body mass index, Treatment and control groups, Pharmaceutical industry

The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.

Key Points: 
  • The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.
  • "Omnipod 5 continues to demonstrate impressive clinical outcomes for people with type 1 diabetes,” said Professor Renard.
  • The control group (n=62) continued to use their usual insulin pump with a Dexcom G6 CGM, while the intervention group (n=132) used Omnipod 5 with Dexcom G6.
  • In conclusion, this multi-national, RCT data demonstrates the superiority of the Omnipod 5 AID System compared to standard pump therapy with CGM and indicates that it should be offered as a first-line therapy for adults with type 1 diabetes.

BIG:LEAP Culminates Guaranteed Income Program

Retrieved on: 
Tuesday, March 28, 2023
University of Southern California, Demographics of Los Angeles, Poverty, Wharton School of the University of Pennsylvania, Employment, Food, Housing, University, Homelessness, Universal basic income, Municipal council, Research, Treatment and control groups, Multimedia, New Mexico Children, Youth, and Families Department, Parenting, City, LEAP, Control, LOS, Shoe, FSCS, Mental health, Family, Treatment, Life insurance, Renewable energy

LOS ANGELES, March 28, 2023 /PRNewswire/ -- Participants of the Basic Income Guaranteed: Los Angeles Economic Assistance Pilot, known as BIG:LEAP, received the final monthly payment of the year-long program on March 25, bringing the payment portion of a program that served more than 3,200 individuals and distributed more than $38.4 million to an end.

Key Points: 
  • LOS ANGELES, March 28, 2023 /PRNewswire/ -- Participants of the Basic Income Guaranteed: Los Angeles Economic Assistance Pilot , known as BIG:LEAP, received the final monthly payment of the year-long program on March 25, bringing the payment portion of a program that served more than 3,200 individuals and distributed more than $38.4 million to an end.
  • "Our Guaranteed Income pilot presented the opportunity to support a simple idea - that families experiencing poverty should be trusted to spend money as they see fit," CIFD General Manager Abigail R. Marquez said.
  • BIG:LEAP's research partner, the University of Pennsylvania's Center for Guaranteed Income Research (CGIR), randomly selected the aforementioned 3,200 participants from over 50,000 applications, and participants received unrestricted monthly payments via a physical debit card managed by MoCaFi .
  • CIFD is also focused on seeking new investment to run a follow-up Guaranteed Income program to continue helping Angeleno families in need.

Imvax Presents New Data on Tumor-Derived Immunotherapies in Glioblastoma, Other Solid Tumors at AACR Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, Glioblastoma, Lymphatic system, Immunotherapy, BDC, Mouse, Liver, Survival, AACR, American Association, Hepatocellular carcinoma, Neoplasm, Gynecologic cancer disparities in the United States, Ovarian cancer, Association, American Association for Cancer Research, Treatment and control groups, Medical imaging

Imvax, Inc. , a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, is presenting data on the activity of the companys tumor-derived immunotherapies in glioblastoma and other solid tumors at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, La.

Key Points: 
  • Imvax, Inc. , a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, is presenting data on the activity of the companys tumor-derived immunotherapies in glioblastoma and other solid tumors at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, La.
  • The data we are presenting at AACR validates the transformative potential of our immunotherapeutic platform to multiple types of solid tumors, said John P. Furey, Chief Executive Officer.
  • Preclinical findings presented at the meeting support the applicability of Imvaxs platform to hepatocellular carcinoma and ovarian and other gynecological cancers.
  • Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors.

Relay Medical Reports Glow LifeTech Secures Exclusive North American Rights to ArtemiC(TM) Following Successful COVID-19 Phase II Clinical Trial

Retrieved on: 
Tuesday, February 16, 2021
Clinical research, Health sciences, Health, Medical research, Design of experiments, Clinical trials, Medical statistics, Pharmaceutical industry, Placebo-controlled study, Placebo, Clinical endpoint, Treatment and control groups

Under the terms of the agreement, signed on February 16, 2021, Glow has exclusive rights to market, sell and distribute ArtemiC in Canada, U.S., Mexico and all Carribean countries as a food supplement.

Key Points: 
  • Under the terms of the agreement, signed on February 16, 2021, Glow has exclusive rights to market, sell and distribute ArtemiC in Canada, U.S., Mexico and all Carribean countries as a food supplement.
  • Recently, MGC announced the results of a Phase II double-blind, placebo-controlled clinical trial, which showed ArtemiC statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the Placebo Group[1].
  • 100% of the patients in the treatment group met the trial's primary endpoint and fully recovered within 15 days.
  • Glow LifeTech is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness.

AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen

Retrieved on: 
Friday, January 29, 2021
Clinical research, Health sciences, Health, Medicine, Design of experiments, Rintatolimod, AIM ImmunoTech, Placebo-controlled study, Clinical trial, Nasal administration, Placebo, Treatment and control groups

OCALA, Fla., Jan. 29, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a sponsorship agreement with the Centre for Human Drug Research (CHDR) for the proposed AMP-COV-100 (CHDR2049) clinical study on the safety of AIMs drug Ampligen as an intranasal therapy, a critical step in the companys ongoing efforts to develop Ampligen as a COVID-19 treatment.

Key Points: 
  • OCALA, Fla., Jan. 29, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a sponsorship agreement with the Centre for Human Drug Research (CHDR) for the proposed AMP-COV-100 (CHDR2049) clinical study on the safety of AIMs drug Ampligen as an intranasal therapy, a critical step in the companys ongoing efforts to develop Ampligen as a COVID-19 treatment.
  • CHDR, an independent institute located in Leiden in the Netherlands, will conduct and manage the proposed clinical study, titled A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subjects.
  • Current study plans call for the enrollment of eight healthy subjects in each of four Ampligen treatment groups and one placebo group, for a total of 40 healthy subjects.
  • They will receive intranasal dosing every other day for 13 days, for a total of seven doses each.

Wize Pharma Announces Meeting Its Phase II Study Primary Objective to Demonstrate LO2A Effectively Treats Dry Eye Syndrome in Patients with Conjunctivochalasis

Retrieved on: 
Tuesday, November 20, 2018
Design of experiments, Clinical research, Health, Placebo-controlled study, Treatment and control groups, Placebo, Medicine, Research

CCh is present in up to one-third of dry eye patients in the US.

Key Points: 
  • CCh is present in up to one-third of dry eye patients in the US.
  • The Phase II multi-center, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of LO2A as compared to placebo in patients with CCh.
  • Patients were randomly assigned in a 1:1 ratio to one of two treatment groups, LO2A or placebo and were treated with topical eye drops for three months.
  • In addition to the above mention study, Wize is currently conducting a randomized, double-masked, study of LO2A versus Alcon's Systane Ultra UD.